OncoMatch/Clinical Trials/NCT07235293
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Is NCT07235293 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including DSP107 + Atezolizumab and Fruquintinib for colorectal cancer.
Treatment: DSP107 + Atezolizumab · Fruquintinib — This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Prior therapy
Must have received: specified therapies
progressed to, or is intolerant to, specified therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colarodo Cancer Center · Aurora, Colorado
- Mayo Clinic · Florida City, Florida
- Duke Cancer Institute - Duke Cancer Center · Durham, North Carolina
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer Center · Texas City, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify